{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:52:29Z","timestamp":1792666349450,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Esophagogastric adenocarcinomas have poor survival, and accurate prognosis assessment is required to guide appropriate treatment. Pre-treatment planning can be challenging and would benefit from non-invasive prognostic tools. Methylated circulating tumor DNA (ctDNA) has prognostic value in colorectal cancer. The aim of the study was to evaluate the prognostic value of methylated ctDNA biomarkers in esophageal and gastric cancers.<\/jats:p>\n                  <jats:p>Circulating cell free DNA, isolated from plasma collected prior to treatment from 122 patients diagnosed with esophagogastric cancer was assayed for methylated BCAT1 and IKZF1. Test positivity was assessed against clinicopathological features, and prognostic factors associated with recurrence-free survival (RFS) and overall survival (OS) were investigated with Cox regression analysis.<\/jats:p>\n                  <jats:p>Methylated BCAT1\/IKZF1 DNA was detected in 54.9% (67\/122) of patients following a diagnosis of esophagogastric cancer. Advanced disease had higher detection rates, with a significant association between test positivity and pathological node-positive disease (odds ratio [OR] for pN2: 5.63, 95% CI 1.27\u201324.86, P\u2009=\u20090.02), and metastatic disease (OR 4.92, 95% CI 1.94\u201312.47, P\u2009&amp;lt;\u20090.01). A positive ctDNA result at diagnosis was associated with worse RFS for individuals considered in remission (hazard ratio [HR] 4.49, 95% CI 1.48\u201313.67, P\u2009&amp;lt;\u20090.01), and a worse OS in all patients (HR 3.64, 95% CI 1.73\u20137.68, P\u2009&amp;lt;\u20090.01), independent of stage and other clinical variables, compared to a negative ctDNA result.<\/jats:p>\n                  <jats:p>Detection of circulating methylated BCAT1\/IKZF1 DNA is a promising prognostic biomarker in esophagogastric cancers. Prospective studies are warranted to investigate the utility of methylated BCAT1\/IKZF1 for monitoring treatment response and for risk stratification to guide adjuvant therapeutic decisions.<\/jats:p>","DOI":"10.1093\/dote\/doag048","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:47:21Z","timestamp":1777376841000},"source":"Crossref","is-referenced-by-count":3,"title":["Assessment of methylated\n                    <i>BCAT1<\/i>\n                    and\n                    <i>IKZF1<\/i>\n                    circulating tumor DNA as a prognostic biomarker in esophagogastric adenocarcinomas"],"prefix":"10.1093","volume":"39","author":[{"given":"Mei Mei","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Oncology, Flinders Medical Centre, Southern Adelaide Local Health Network , Bedford Park, South Australia ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitesh C","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Oncology, Flinders Medical Centre, Southern Adelaide Local Health Network , Bedford Park, South Australia ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7683-2693","authenticated-orcid":false,"given":"David I","family":"Watson","sequence":"additional","affiliation":[{"name":"Department of Surgery, Flinders Medical Centre, Southern Adelaide Local Health Network , Bedford Park, South Australia ,","place":["Australia"]},{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University , Bedford Park, South Australia ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Bright","sequence":"additional","affiliation":[{"name":"Department of Surgery, Flinders Medical Centre, Southern Adelaide Local Health Network , Bedford Park, South Australia ,","place":["Australia"]},{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University , Bedford Park, South Australia ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Sheehan-Hennessy","sequence":"additional","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University , Bedford Park, South Australia ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme P","family":"Young","sequence":"additional","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University , Bedford Park, South Australia ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Hussey","sequence":"additional","affiliation":[{"name":"Department of Surgery, Flinders Medical Centre, Southern Adelaide Local Health Network , Bedford Park, South Australia ,","place":["Australia"]},{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University , Bedford Park, South Australia ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne K","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University , Bedford Park, South Australia ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M","family":"Winter","sequence":"additional","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University , Bedford Park, South Australia ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2451-0358","authenticated-orcid":false,"given":"Erin L","family":"Symonds","sequence":"additional","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University , Bedford Park, South Australia ,","place":["Australia"]},{"name":"Department of Gastroenterology, Flinders Medical Centre, Southern Adelaide Local Health Network , Bedford Park, South Australia ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"1","key":"2026051810544253300_ref1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2026051810544253300_ref2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1002\/ijc.32580","article-title":"Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: a real-world evidence study","volume":"146","author":"Dijksterhuis","year":"2020","journal-title":"Int J Cancer\/ Journal international du cancer"},{"issue":"10294","key":"2026051810544253300_ref3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet."},{"issue":"8","key":"2026051810544253300_ref4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082654","article-title":"Pattern of recurrence and patient survival after perioperative chemotherapy with 5-FU, Leucovorin, Oxaliplatin and docetaxel (FLOT) for locally advanced Esophagogastric adenocarcinoma in patients treated outside clinical trials","volume":"9","author":"Glatz","year":"2020","journal-title":"J Clin Med"},{"issue":"8","key":"2026051810544253300_ref5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term efficacy of Neoadjuvant Chemoradiotherapy plus surgery for the treatment of locally advanced Esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg"},{"issue":"13","key":"2026051810544253300_ref6","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"2026051810544253300_ref7","doi-asserted-by":"publisher","first-page":"S289","DOI":"10.3978\/j.issn.2072-1439.2014.03.11","article-title":"Esophageal cancer: staging system and guidelines for staging and treatment","volume":"6 Suppl 3","author":"Berry","year":"2014","journal-title":"J Thorac Dis"},{"issue":"10","key":"2026051810544253300_ref8","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol \/ ESMO"},{"issue":"10","key":"2026051810544253300_ref9","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannova","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol \/ ESMO"},{"issue":"3","key":"2026051810544253300_ref10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.7497\/j.issn.2095-3941.2013.03.005","article-title":"Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis)","volume":"10","author":"Bagaria","year":"2013","journal-title":"Cancer Biol Med"},{"issue":"2","key":"2026051810544253300_ref11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.15386\/cjmed-409","article-title":"Classic tumor markers in gastric cancer","volume":"88","author":"Cainap","year":"2015","journal-title":"Curr Standards Limitations Clujul Med"},{"key":"2026051810544253300_ref12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fmed.2018.00009","article-title":"Liquid biopsy in clinical Management of Breast, lung, and colorectal cancer","volume":"5","author":"Hench","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"2026051810544253300_ref13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/1541-7786.MCR-19-0768","article-title":"Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical Management of Cancer","volume":"18","author":"Oliveira","year":"2020","journal-title":"Mol Cancer Res : MCR"},{"issue":"4","key":"2026051810544253300_ref14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"2026051810544253300_ref15","doi-asserted-by":"publisher","first-page":"6248","DOI":"10.1158\/1078-0432.CCR-18-1128","article-title":"Analysis of circulating tumor DNA and clinical correlates in patients with Esophageal, gastroesophageal junction, and gastric adenocarcinoma","volume":"24","author":"Kato","year":"2018","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"2","key":"2026051810544253300_ref16","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doab046","article-title":"Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis","volume":"35","author":"Chidambaram","year":"2022","journal-title":"Dis Esophagus"},{"issue":"5","key":"2026051810544253300_ref17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s10120-022-01313-w","article-title":"Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer","volume":"25","author":"Velzen","year":"2022","journal-title":"Gastric Cancer : Off J Int Gastric Cancer Assoc Japanese Gastric Cancer Assoc"},{"issue":"2","key":"2026051810544253300_ref18","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1097\/SLA.0000000000005177","article-title":"Potential clinical utility of a targeted circulating tumor DNA assay in Esophageal adenocarcinoma","volume":"276","author":"Cabalag","year":"2022","journal-title":"Ann Surg"},{"issue":"9","key":"2026051810544253300_ref19","doi-asserted-by":"publisher","first-page":"e00202","DOI":"10.14309\/ctg.0000000000000202","article-title":"Targeted sequencing of sorted Esophageal adenocarcinoma cells unveils known and novel mutations in the separated subpopulations","volume":"11","author":"Isidori","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"12","key":"2026051810544253300_ref20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154941","article-title":"Circulating tumor DNA: current challenges for clinical utility","volume":"132","author":"Dang","year":"2022","journal-title":"J Clin Invest"},{"key":"2026051810544253300_ref21","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.3389\/fgene.2019.01150","article-title":"DNA methylation cancer biomarkers: translation to the clinic","volume":"10","author":"Locke","year":"2019","journal-title":"Front Genet"},{"key":"2026051810544253300_ref22","doi-asserted-by":"publisher","first-page":"e2100181","DOI":"10.1200\/PO.21.00181","article-title":"Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and Design of Clinical Trials for solid Tumors","volume":"6","author":"Kasi","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026051810544253300_ref23","doi-asserted-by":"publisher","first-page":"e934106","DOI":"10.12659\/MSM.934106","article-title":"A review of circulating tumor DNA in the diagnosis and monitoring of Esophageal cancer","volume":"28","author":"Min","year":"2022","journal-title":"Med Sci Monit"},{"key":"2026051810544253300_ref24","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1038\/ctg.2015.67","article-title":"A blood test for methylated BCAT1 and IKZF1 vs. a Fecal immunochemical test for detection of colorectal neoplasia","volume":"7","author":"Symonds","year":"2016","journal-title":"Clin Transl Gastro"},{"issue":"7","key":"2026051810544253300_ref25","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/cncr.32695","article-title":"Circulating epigenetic biomarkers for detection of recurrent colorectal cancer","volume":"126","author":"Symonds","year":"2020","journal-title":"Cancer."},{"key":"2026051810544253300_ref26","doi-asserted-by":"publisher","first-page":"11772719241232870","DOI":"10.1177\/11772719241232870","article-title":"Evaluating the role of methylated circulating tumor DNA in combination with pathological prognostic factors for predicting recurrence of colorectal cancer","volume":"19","author":"Al Naji","year":"2024","journal-title":"Biomark Insights"},{"issue":"4","key":"2026051810544253300_ref27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/1354750X.2024.2340663","article-title":"BCAT1, IKZF1 and SEPT9: methylated DNA biomarkers for detection of pan-gastrointestinal adenocarcinomas","volume":"29","author":"Laven-Law","year":"2024","journal-title":"Biomarkers."},{"issue":"2","key":"2026051810544253300_ref28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.21037\/acs.2017.03.14","article-title":"8th edition AJCC\/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice","volume":"6","author":"Rice","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"issue":"11","key":"2026051810544253300_ref29","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","article-title":"Classification of adenocarcinoma of the oesophagogastric junction","volume":"85","author":"Siewert","year":"1998","journal-title":"Br J Surg"},{"key":"2026051810544253300_ref30","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1186\/s12885-015-1674-2","article-title":"Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia","volume":"15","author":"Pedersen","year":"2015","journal-title":"BMC Cancer"},{"issue":"4","key":"2026051810544253300_ref31","doi-asserted-by":"publisher","first-page":"e0125041","DOI":"10.1371\/journal.pone.0125041","article-title":"A two-gene blood test for methylated DNA sensitive for colorectal cancer","volume":"10","author":"Pedersen","year":"2015","journal-title":"PloS One"},{"issue":"10","key":"2026051810544253300_ref32","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/1878-0261.13178","article-title":"Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1\/IKZF1","volume":"16","author":"Symonds","year":"2022","journal-title":"Mol Oncol"},{"issue":"7","key":"2026051810544253300_ref33","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1097\/JS9.0000000000001373","article-title":"Association between plasma circulating tumor DNA and the prognosis of esophageal cancer patients: a meta-analysis","volume":"110","author":"Zhang","year":"2024","journal-title":"Int J Surg"},{"key":"2026051810544253300_ref34","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3389\/fonc.2018.00610","article-title":"The potential clinical utility of circulating tumor DNA in Esophageal adenocarcinoma: from early detection to therapy","volume":"8","author":"Kosovec","year":"2018","journal-title":"Front Oncol"},{"issue":"23","key":"2026051810544253300_ref35","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","article-title":"Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma","volume":"25","author":"Maron","year":"2019","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"9","key":"2026051810544253300_ref36","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol \/ ESMO."},{"issue":"5","key":"2026051810544253300_ref37","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41419-020-2531-z","article-title":"Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Cell Death Dis"},{"issue":"20","key":"2026051810544253300_ref38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205105","article-title":"The role of ctDNA in gastric cancer","volume":"14","author":"Mencel","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2026051810544253300_ref39","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41416-020-1002-8","article-title":"Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma","volume":"123","author":"Openshaw","year":"2020","journal-title":"Br J Cancer"},{"key":"2026051810544253300_ref40","doi-asserted-by":"publisher","first-page":"1608872","DOI":"10.3389\/fonc.2025.1608872","article-title":"Circulating tumor DNA predicts prognosis at different time points in patients with esophageal cancer: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"issue":"8","key":"2026051810544253300_ref41","doi-asserted-by":"publisher","first-page":"e0256436","DOI":"10.1371\/journal.pone.0256436","article-title":"Clinical correlates of circulating cell-free DNA tumor fraction","volume":"16","author":"Bredno","year":"2021","journal-title":"PloS One"},{"issue":"3","key":"2026051810544253300_ref42","doi-asserted-by":"publisher","first-page":"e0230622","DOI":"10.1371\/journal.pone.0230622","article-title":"Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation","volume":"15","author":"Cho","year":"2020","journal-title":"PloS One"},{"issue":"42","key":"2026051810544253300_ref43","doi-asserted-by":"publisher","first-page":"e12862","DOI":"10.1097\/MD.0000000000012862","article-title":"Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: a meta-analysis","volume":"97","author":"Lee","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2026051810544253300_ref44","doi-asserted-by":"publisher","first-page":"e2200420","DOI":"10.1200\/PO.22.00420","article-title":"Analysis of circulating tumor DNA to predict risk of recurrence in patients with Esophageal and gastric cancers","volume":"6","author":"Huffman","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026051810544253300_ref45","doi-asserted-by":"publisher","first-page":"e2400288","DOI":"10.1200\/PO.24.00288","article-title":"Circulating tumor DNA as a prognostic biomarker for recurrence in patients with Locoregional Esophagogastric cancers with a pathologic complete response","volume":"8","author":"Lander","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"2026051810544253300_ref46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10120-024-01556-9","article-title":"Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer","volume":"28","author":"Iden","year":"2025","journal-title":"Gastric Cancer : Off J Int Gastric Cancer Assoc Japanese Gastric Cancer Assoc"},{"issue":"3","key":"2026051810544253300_ref47","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","article-title":"Circulating tumor DNA analysis for detection of minimal residual disease after Chemoradiotherapy for localized Esophageal cancer","volume":"158","author":"Azad","year":"2020","journal-title":"Gastroenterology."},{"issue":"1","key":"2026051810544253300_ref48","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1038\/s41467-025-62056-7","article-title":"Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study","volume":"16","author":"Zaanan","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"2026051810544253300_ref49","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"2026051810544253300_ref50","doi-asserted-by":"publisher","first-page":"473","DOI":"10.5306\/wjco.v13.i6.473","article-title":"Circulating tumor DNA for diagnosis, prognosis and treatment of gastrointestinal malignancies","volume":"13","author":"Kirchweger","year":"2022","journal-title":"World J Clin Oncol"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/3\/doag048\/68325182\/doag048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/3\/doag048\/68325182\/doag048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:54:52Z","timestamp":1779116092000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doag048\/8685689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doag048","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,12]]},"article-number":"doag048"}}